Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system-Reference-Cited by-同舟云学术

Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system

Published:2024-08-29 Issue:1 Volume:5 Page:
ISSN:2662-2211
Container-title:Implementation Science Communications
language:en
Short-container-title:Implement Sci Commun

Author:

Agovi Afiba Manza-A,Thompson Caitlin T.,Craten Kevin J.,Fasanmi Esther,Pan Meng,Ojha Rohit P.,Thompson Erika L.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s43058-024-00631-7.pdf

Reference72 articles.

1. Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masia M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112–23.

2. Food and Drug Adminstration (FDA). FDA approves cabenuva and vocabria for the treatment of HIV-1 infection January 27, 2021. 2022. Available from: https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection.

3. Cabotegravir and rilpivirine drug information. 2022. Available from: https://clinicalinfo.hiv.gov/en/drugs/cabotegravir-rilpivirine/patient. Cited 11/18/2022.

4. Cabenuva [package insert]. Silver Spring, MD: U.S. Food and Drug Administration; 2022. cited 2024 Aug 22. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf.

5. ViiV Healthcare. ViiV Healthcare announces FDA approval of Cabenuva for use every two months [Internet]. 2022 Jan 31. cited 2023 Feb 2. Available from: https://viivhealthcare.com/hiv-news-and-media/news/pressreleases/2022/january/viiv-healthcare-announces-fda-approval-of-cabenuva-for-use-every-two-months/.